Update on daptomycin: the first approved lipopeptide antibiotic.
Daptomycin, the first approved member of the lipopeptide antibiotic class, exhibits potent bactericidal in vitro activity against most Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus species and penicillin-resistant Streptococcus species. Since its approval in 2003 for the treatment of complicated skin and skin structure infections, several review articles have summarised daptomycin's mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials and safety profiles. The objective of this paper is to summarise past information with a focus on the latest susceptibility data of isolates collected worldwide, new pharmacodynamic studies, clinical data regarding bacteraemia/endocarditis and postmarketing surveillance in the treatment of skin and skin-structure infections.
Lee
Su Young
SY
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA.
Fan
Hong Wei
HW
Kuti
Joseph L
JL
Nicolau
David P
DP
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017576:Daptomycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D016983:Enterococcus / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D017576:Daptomycin